V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Amphastar Pharmaceuticals Executive Compensation (FY25)

AMPH · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Jack Yongfeng Zhang
Latest say-on-pay support
=
June 1, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Amphastar Pharmaceuticals brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 17, 2026Latest filing (8-K): June 3, 2026
7 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Amphastar Pharmaceuticals brief$1,500Get the executive brief
Velarion Member, one year
308 figures on this page: 306 cited to the filing that reported them, 2 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive of record: Jack Zhang → Jack Yongfeng Zhang
CEO pay ratio: 94:1 → 135:1 (43.6% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Amphastar Pharmaceuticals' chief executive and what were they paid?
Jack Yongfeng Zhang was paid $8,309,350 in total compensation as Chief Executive Officer, President, Chief Scientific Officer and Director for fiscal 2025.
What was Amphastar Pharmaceuticals' say-on-pay result?
Shareholders recorded 91.8% support for the say-on-pay proposal at the meeting held June 1, 2026 for fiscal 2025.
Which companies are in Amphastar Pharmaceuticals' peer group?
Companies named in the disclosed peer group include ACADIA Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Amicus Therapeutics, Inc., ANI Pharmaceuticals, Inc. and Collegium Pharmaceuticals, Inc., among others.
What is Amphastar Pharmaceuticals' chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 135:1, against median employee compensation of $61,658.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jack Yongfeng Zhang
Chief Executive Officer, President, Chief Scientific Officer
◇◇◇◇◇—◇◇
Mary Ziping Luo
Chief Operating Officer, Chief Scientist and Chairman
◇◇◇◇◇—◇◇
William Peters
Chief Financial Officer, Executive Vice President of Finance, Treasurer, President of International Medication Systems, Limited, and Director
◇◇◇◇◇—◇◇
Rong Zhou
Senior Executive Vice President of Production and President of. Amphastar Nanjing Pharmaceuticals, Co., Ltd
◇◇◇◇◇—◇◇
Jacob Liawatidewi
Executive Vice President of Sales and Marketing, Executive Vice President of Corporate Administration Center and President of Amphastar France Pharmaceuticals, S.A.S.
◇◇◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jack Zhang
Chief Executive Officer, President, Chief Scientific Officer and Director
◇◇◇◇◇—◇◇
Mary Luo
Chief Operating Officer, Chief Scientist and Chairman of the Board of Directors
◇◇◇◇◇—◇◇
William Peters
Chief Financial Officer, Executive Vice President of Finance, Treasurer, President of International Medication Systems, Limited, and Director
◇◇◇◇◇—◇◇
Rong Zhou
Senior Executive Vice President of Production Center; Executive Vice President of Scientific Affairs and President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
◇◇◇◇◇—◇◇
Jacob Liawatidewi
Executive Vice President of Sales and Marketing and Corporate Administration Center, President of Amphastar France Pharmaceuticals, S.A.S., Corporate Secretary, and Director
◇◇◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jack Zhang
Chief Executive Officer, President, Chief Scientific Officer and Director
◇◇◇◇◇—◇◇
Mary Luo
Chief Operating Officer, Chief Scientist and Chairman of the Board of Directors
◇◇◇◇◇—◇◇
William Peters
Chief Financial Officer, Executive Vice President of Finance, Treasurer, President of International Medication Systems, Limited, and Director
◇◇◇◇◇—◇◇
Rong Zhou
Senior Executive Vice President of Production Center; Executive Vice President of Scientific Affairs and President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
◇◇◇◇◇—◇◇
Jacob Liawatidewi
Executive Vice President of Sales and Marketing and Corporate Administration Center, President of Amphastar France Pharmaceuticals, S.A.S., Corporate Secretary and Director
◇◇◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jack Yongfeng Zhang
Chief Executive Officer, President, Chief Scientific Officer and Director
◇◇◇◇◇—◇◇
Mary Ziping Luo
Chief Operating Officer, Chief Scientist and Chairman of the Board of Directors
◇◇◇◇◇—◇◇
William Peters
Chief Financial Officer, Executive Vice President of Finance, Treasurer, President of International Medication Systems, Limited, and Director
◇◇◇◇◇—◇◇
Rong Zhou
Senior Executive Vice President of Production Center; Executive Vice President of Scientific Affairs and President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
◇◇◇◇◇—◇◇
Jacob Liawatidewi
Executive Vice President of Sales and Marketing and Corporate Administration Center, President of Amphastar France Pharmaceuticals, S.A.S., Corporate Secretary and Director
◇◇◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Jack Y. ZhangRSU◇——◇——◇
Jack Y. ZhangOPTION◇——◇—◇◇
Jacob LiawatidewiRSU◇——◇——◇
Jacob LiawatidewiOPTION◇——◇—◇◇
Mary Z. LuoRSU◇——◇——◇
Mary Z. LuoOPTION◇——◇—◇◇
Rong ZhouRSU◇——◇——◇
Rong ZhouOPTION◇——◇—◇◇
William J. PetersRSU◇——◇——◇
William J. PetersOPTION◇——◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
William PetersOption◇—◇3/15/32
RSU◇◇——
Option◇—◇3/10/35
RSU◇◇——
RSU◇◇——
Option◇—◇3/4/34
RSU◇◇——
Option◇—◇3/6/33
Jack Yongfeng ZhangOption◇—◇3/10/35
RSU◇◇——
RSU◇◇——
Option◇—◇3/15/32
Option◇—◇3/6/33
RSU◇◇——
RSU◇◇——
Option◇—◇3/4/34
Mary Ziping LuoOption◇—◇3/4/34
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/6/33
Option◇—◇3/15/32
Option◇—◇3/10/35
Jacob LiawatidewiOption◇—◇3/6/33
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/10/35
RSU◇◇——
Option◇—◇3/15/32
Rong ZhouRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/15/32
RSU◇◇——
Option◇—◇3/4/34
Option◇—◇3/10/35
Option◇—◇3/6/33
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Jacob Liawatidewi
Executive Vice President of Sales and Marketing and Corporate Administration Center, President of Amphastar France Pharmaceuticals, S.A.S., Corporate Secretary and Director · Terms as announced by the company
Severance multiple◇
Change-in-control multiple◇
Equity acceleration on change in control◇
Benefits continuation◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Richard Prins
Lead independent director
◇◇◇———◇
Gayle Deflin
◇◇◇———◇
Howard Lee
◇◇◇———◇
Michael A. Zasloff
◇◇◇———◇
Diane Gerst
◇◇◇———◇
Floyd F. Petersen
◇◇◇———◇
David Gaugh
◇◇◇———◇
Mary Ziping Luo, Jack Yongfeng Zhang, Jacob Liawatidewi and William J. Peters served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • ACADIA Pharmaceuticals, Inc. ACAD
  • Alnylam Pharmaceuticals, Inc. ALNY
  • Amicus Therapeutics, Inc. FOLD
  • ANI Pharmaceuticals, Inc. ANIP
  • Collegium Pharmaceuticals, Inc. COLL
  • Corcept Therapeutics Inc. CORT
  • Emergent BioSolutions Inc. EBS
  • Exelixis, Inc. EXEL
  • Halozyme Therapeutics, Inc. HALO
  • Ionis Pharmaceuticals, Inc. IONS
  • Ironwood Pharmaceuticals, Inc. IRWD
  • Pacira BioSciences, Inc. PCRX
  • Prestige Consumer Healthcare, Inc. PBH
  • PTC Therapeutics, Inc. PTCT
  • Sarepta Therapeutics, Inc. SRPT
  • Supernus Pharmaceuticals, Inc. SUPN

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 1, 2026=◇◇◇
2024June 2, 2025=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Jack Yongfeng Zhang (Chief Executive Officer, President, Chief Scientific Officer and Director), FY2025 total compensation $8,309,350 (base salary $950,911) [exec_comp, SEC accession 0001297184-26-000023, filed 2026-04-13]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Amphastar Pharmaceuticals files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Amphastar Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Amphastar Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Amphastar Pharmaceuticals' disclosed peer group is defensible, who names Amphastar Pharmaceuticals back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
308 figures on this page: 306 cited to the filing that reported them, 2 calculated from figures it prints.
306 cited to the filing
2 calculated from the filing

Documents cited

  1. 0001297184-26-000038
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001297184-26-000023
    2025 Grants of Plan-Based Awards · CEO Pay Ratio · Director Compensation for 2025 · Fiscal 2025 Summary Compensation Table · and 2 more sections
  3. 0001297184-26-000015
    Exhibit
  4. 0001297184-25-000036
    Item 5.07 Submission of Matters to a Vote of Security Holders
  5. 0001297184-25-000018
    Fiscal 2024 Summary Compensation Table
  6. 0001297184-24-000019
    Fiscal 2023 Summary Compensation Table
  7. 0001297184-23-000033
    Fiscal 2022 Summary Compensation Table
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Amphastar Pharmaceuticals executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/AMPH (accessed 2026).
Short form: data: Velarion

The Amphastar Pharmaceuticals brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
7 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Amphastar Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Amphastar Pharmaceuticals discloses

The companies named in AMPH's own disclosed peer group.

ACADIA Pharmaceuticals, Inc.Alnylam Pharmaceuticals, Inc.Amicus Therapeutics, Inc.ANI Pharmaceuticals, Inc.Collegium Pharmaceuticals, Inc.Corcept Therapeutics Inc.Emergent BioSolutions Inc.Exelixis, Inc.Halozyme Therapeutics, Inc.Ionis Pharmaceuticals, Inc.Ironwood Pharmaceuticals, Inc.Pacira BioSciences, Inc.Prestige Consumer Healthcare, Inc.PTC Therapeutics, Inc.Sarepta Therapeutics, Inc.Supernus Pharmaceuticals, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy